Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 8/20 | 0.56 |
| ▸ | CD69 | Q07108 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | FGF1 | P05230 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.37 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26878914 | 0.88 | LGALS8 (0.46) | LGALS8CYP2D6THRBHSD17B10 | |
| SCHEMBL13658762 | 0.88 | LGALS8 (0.49) | LGALS8CD69PTPN1FGF1LGALS3 | |
| SCHEMBL29220914 | 0.88 | LGALS8 (0.71) | LGALS8CD69PTPN1LGALS3LGALS9 | |
| SCHEMBL13419004 | 0.88 | LGALS8 (0.44) | LGALS8CD69FGF1LGALS3LGALS9 | |
| SCHEMBL12410177 | 0.88 | LGALS8 (0.44) | LGALS8CD69FGF1LGALS3LGALS9 | |
| SCHEMBL15498430 | 0.87 | LGALS8 (0.62) | LGALS8FGF1LGALS3THRB | |
| SCHEMBL13419006 | 0.85 | CYP2D6 (0.49) | LGALS8CYP2D6THRBHSD17B10 | |
| SCHEMBL12410178 | 0.85 | CYP2D6 (0.49) | LGALS8CYP2D6THRBHSD17B10 | |
| SCHEMBL13658767 | 0.84 | LGALS8 (0.44) | LGALS8CD69FGF1LGALS9CYP2D6 | |
| SCHEMBL16327733 | 0.83 | LGALS8 (0.60) | LGALS8CD69PTPN1FGF1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387252-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9040033-B2 | Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution | DOW GLOBAL TECHNOLOGIES LLC | 2015-05-26 | — | — | US | disclosed |
| US-8940800-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130102691-A1 | HYDROXYPROPYL METHYL CELLULOSE ACETATE SUCCINATE WITH ENHANCED ACETATE AND SUCCINATE SUBSTITUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120264833-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | LONZA BEND INC. | 2012-10-18 | — | — | US | disclosed |
| US-8207232-B2 | Pharmaceutical compositions with enhanced performance | BEND RESEARCH, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20080262107-A1 | A solid amorphous dispersion of a low-soluble drug and hydroxypropylmethyl celllulose acetate succinate with an ester degree of substitution of 0.85 which results in concentration-enhancement, time release agents, and storage stability; rapid crystal growth inhibitors in supersaturated aqueous solutions | PFIZER PRODUCTS INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102691-A1 | HYDROXYPROPYL METHYL CELLULOSE ACETATE SUCCINATE WITH ENHANCED ACETATE AND SUCCINATE SUBSTITUTION | HPD, CS, PCCA | LGALS8 2357/4885CD69 2925/4885PTPN1 3583/4885 |
| US-20080262107-A1 | A solid amorphous dispersion of a low-soluble drug and hydroxypropylmethyl celllulose acetate succinate with an ester degree of substitution of 0.85 which results in concentration-enhancement, time release agents, and storage stability; rapid crystal growth inhibitors in supersaturated aqueous solutions | HPD, HAAO, SUCLA2 | LGALS8 2915/4885CD69 861/4885PTPN1 3174/4885 |
| US-20120264833-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | HPD, HAAO, MCCC2 | LGALS8 1999/4885CD69 3071/4885PTPN1 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.